COST SAVING ASSOCIATED WITH GLUCOSE METER ACCURACCY IN SPAIN

Author(s)

Sanz-Granda Á¹, Artola-Menéndez S², Franch-Nadal J³, Gonzalez-Gutiérrez JA⁴, Hidalgo-Vega Á¹, Mata-Cases M², Merino-Torres JF⁵, Vicente-Sánchez C⁶
¹Weber Economía y Salud (WEYS), Majadahonda, Spain, ²Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain, ³EAP Raval Sud- Institut Català de la Salut - USR Barcelona ciutat - IDIAP Jordi Gol, Barcelona, Spain, ⁴Osakidetza, San Sebastián, Spain, ⁵Hospital La Fe, Valencia, Spain, ⁶Consejería de Salud Illes Balears, Palma, Spain

Presentation Documents

PMD40--strong-u-sanz-granda-a-u-sup-1-sup-strong-artola-menendez-s-sup-2-sup-franch-nadal-j-sup-3-sup-gonzalez-gutierrez-ja-sup-4-sup-hidalgo-vega-a-sup-1-sup-mata-cases-m-sup-2-sup-merino-torres-jf-sup-5-sup-vicente-sanchez-c-sup-6-sup-br- ...

OBJECTIVES: ISO 15197:2003, states that 95% of the glucose results shall fall within ±15 mg/dl for concentrations ≤75 mg/dl and within ±20% for >75 mg/dl. Some measures which may fall into the recommended thresholds would be out of the limits of good metabolic control, not permitting to adjust the therapy, increasing the complication risk, and raising the associated costs. The objective was to estimate the annual cost saving in Spain by using glucose meters with better accuracy

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PMD40

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Presentation